Overview

* Thermo Fisher Q3 revenue grows 5% to $11.12 bln, beating analyst expectations

* Adjusted EPS for Q3 rises 10% to $5.79, exceeding analyst estimates

* Company completed acquisitions and collaborated with OpenAI to enhance productivity

Outlook

* Company to provide updated 2025 guidance during its earnings call

Result Drivers

* INNOVATIVE PRODUCTS - Launch of new products like Oncomine Dx Express Test and Olink Target 48 Neurodegeneration panel contributed to growth

* STRATEGIC ACQUISITIONS - Acquisitions of Filtration and Separation business from Solventum and Sanofi's sterile fill-finish site expanded capabilities

* AI COLLABORATION - Partnership with OpenAI to enhance AI use in operations and products to accelerate scientific breakthroughs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $11.12 $10.90

Revenue bln bln (18

Analysts

)

Q3 Beat $5.79 $5.49

Adjusted (20

EPS Analysts

)

Q3 EPS $4.27

Q3 Beat $2.19 $2.07

Adjusted bln bln (17

Net Analysts

Income )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Thermo Fisher Scientific Inc ( TMO ) is $562.50, about 0.8% above its October 21 closing price of $557.99

* The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)